In a large population of people with diabetes, the use of GLP-1 receptor agonists was not linked to an increased risk for ...

Sales results disclosed Tuesday raised concern that investors may have overestimated the demand for Zepbound and Mounjaro.

Digital health companies' plans focused on managing the impact of GLP-1 drugs, which have placed enormous pressure on health ...

For patients with diabetes undergoing a surgical procedure, an active perioperative glucagon-like peptide-1 receptor agonist (GLP-1 RA) prescription is associated with reductions in risk-adjusted ...

While weight loss is a common new year's resolution for workers in the U.S., 2025 may mark the year that building weight loss ...

The governor also said she would work with other states to leverage their combined purchasing power to reduce the cost of the ...

Drugs like Ozempic, Wegovy and Mounjaro are changing the game for weight loss. GLP-1 medications were originally intended to ...

Semaglutide combined with automated insulin delivery enhances glucose control in type 1 diabetes, lowering insulin ...

New drugs from public and private companies are ... These new challengers are anticipated to account for roughly $70 billion of the total GLP-1 market, which is expected to be worth $200 billion ...

A study by Mass General Brigham investigators shows persistent racial disparities and growing sex disparities between ...

Many of them are on Medicaid and have become yo-yo dieters who, despite their best efforts at changing their eating habits and lifestyles, cannot seem to shed the pounds hurting their health. “They ...

Semaglutide (known by its brand name Ozempic) has gained widespread attention for its weight-loss benefits, but is officially ...